T-Cell Prolymphocytic Leukemia · line 1 · Alemtuzumab IV — disease-defining anti-CD52, 12 weeks induction
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-ALEMTUZUMAB-IV |
| ID | IND-T-PLL-1L-ALEMTUZUMAB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-T-PLL |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
STUB. T-PLL — дуже rare; refer до tertiary center з allo-SCT capability. Alemtuzumab access — bottleneck в Україні (off-label для T-PLL).
Used By
Algorithms
ALGO-T-PLL-1L- ALGO-T-PLL-1L
Contraindications
CI-ACTIVE-INFECTION-FOR-ALEMTUZUMAB- CI-ACTIVE-INFECTION-FOR-ALEMTUZUMAB